Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Alto Neuroscience Inc.

ANRO

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Last trade $25.12
Day change -$2.00 (-7.37%)
Day range $25.00 – $27.82
Volume 262,215
Market cap $1.09B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.09B
Price / earnings
—
Price / book
3.67×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.86×

Profitability

Earnings per share
-$2.37
Return on assets
-29.15%
Return on equity
-32.1%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.05×
Current ratio
18.12×
Quick ratio
18.12×
Cash ratio
17.9×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$79.68M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ANRO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$9.06M$7.02M$6.84M$5.06M$4.43M$5.56M$5.7M$6.2M
Research and development$18.16M$22.11M$20.29M$12M$10.53M$13.12M$9.97M$10.8M
Total operating expenses$27.23M$29.13M$27.14M$17.06M$14.95M$18.68M$15.68M$17M
Operating income-$27.23M-$29.13M-$27.14M-$17.06M-$14.95M-$18.68M-$15.68M-$17M
Interest expense-$463K-$491K-$545K-$575K-$650K-$646K-$598K-$333K
Income before taxes-$25.12M-$27.64M-$26.24M-$16.18M-$14.18M-$17.71M-$15.17M-$15.2M
Income taxes$0$0$0$0$0$0$0$0
Net income-$25.12M-$27.64M-$26.24M-$16.18M-$14.18M-$17.71M-$15.17M-$15.2M
Net income attributable to common shareholders-$25.12M-$27.64M-$26.24M-$16.18M-$14.18M-$17.71M-$15.17M-$15.2M
EBITDA-$27.04M-$28.95M-$26.95M-$16.9M-$14.79M-$18.51M-$15.51M-$16.83M
Basic earnings per share-$0.54-$0.65-$0.80-$0.47-$0.52-$0.65-$0.56-$0.56
Diluted earnings per share-$0.54-$0.65-$0.80-$0.47-$0.52-$0.65-$0.56-$0.56

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?

UnitedHealth Group (UNH) has gained 24.8% year-to-date, outperforming the broader Medical sector's 9% average gain. The company holds a Zacks Rank #2 (Buy) with improved analyst sentiment, as consensus earnings estimates have risen 4.6% in the past quarter. However, UNH slightly underperforms its Medical-HMOs industry group, which has averaged 28.6% gains. Alto Neuroscience (ANRO) is also highlighted as an outperformer with 52.4% year-to-date returns.

Zacks Investment Research

Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know

Alto Neuroscience, Inc. (ANRO) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and positive earnings estimate revisions.

Zacks Investment Research

Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know

Alto Neuroscience (ANRO) has gained 34.6% over the past four weeks and Wall Street analysts predict a potential 29.4% upside with a mean price target of $38.22. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, with four estimates moving higher over the last 30 days and a 7% increase in consensus estimates. However, the article cautions that price targets should not be the sole basis for investment decisions.

Zacks Investment Research

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.

Benzinga

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.